SMS Pharmaceuticals Limited (IN:SMSPHARMA)
:SMSPHARMA
SMSPHARMA Stock Chart & Stats
₹325.40
-₹5.32(-2.16%)
At close: 4:00 PM EST
₹325.40
-₹5.32(-2.16%)
Day’s Range― - ―
52-Week Range₹175.00 - ₹433.80
Previous CloseN/A
Volume71.57K
Average Volume (3M)105.50K
Market Cap
₹36.41B
Enterprise Value₹38.61B
Total Cash (Recent Filing)₹1.02B
Total Debt (Recent Filing)₹3.24B
Price to Earnings (P/E)30.0
Beta1.54
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.13%
Share Statistics
EPS (TTM)2.51
Shares Outstanding93,652,030
10 Day Avg. Volume15,241
30 Day Avg. Volume105,503
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)2.91
Price to Sales (P/S)2.38
P/FCF Ratio-31.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthConsistent revenue growth from 2020–2025 indicates durable demand for the company's API portfolio and expanding market penetration. Over 2–6 months this supports stable capacity utilization, stronger supplier/customer bargaining, and predictable scale benefits that underpin long-term cash generation and strategic investment.
Healthy Operating MarginsSustained EBIT/EBITDA margins point to manufacturing efficiency and pricing power in niche APIs. Margin resilience allows SMS to absorb raw material swings, fund maintenance and regulatory compliance, and finance selective R&D or capacity expansion—supporting profitability stability across cycles.
Moderate Leverage / Strong EquityA balanced debt-to-equity profile and solid equity backing provide financial flexibility for reinvestment, working capital, and export qualification processes. This structural balance reduces refinancing risk, enabling sustained operations and investment in compliance/capacity over the medium term.
Bears Say
Volatile Net IncomeA pronounced net income decline in 2023 that produced a negative net margin undermines earnings quality and predictability. For management and investors this raises concerns about cost control, product mix risks, or one-off losses, complicating long-term planning for capex, dividends, and strategic initiatives.
Inconsistent Free Cash FlowMaterial FCF volatility and occasional negative years suggest uneven cash conversion from operations, possibly due to capex cycles or working capital swings. Persistent variability can constrain internal funding for growth, increase reliance on external financing, and elevate liquidity risk during industry shocks.
Rising Debt Levels To MonitorNoted increases in debt raise leverage and interest cost exposure, which can erode financial flexibility. Higher leverage amplifies downside risk from earnings volatility and may limit ability to invest in GMP upgrades or supplier diversification, making covenant and refinancing risk relevant over the medium term.
SMS Pharmaceuticals Limited News
SMSPHARMA FAQ
What was SMS Pharmaceuticals Limited’s price range in the past 12 months?
SMS Pharmaceuticals Limited lowest stock price was ₹175.00 and its highest was ₹433.80 in the past 12 months.
What is SMS Pharmaceuticals Limited’s market cap?
SMS Pharmaceuticals Limited’s market cap is ₹36.41B.
When is SMS Pharmaceuticals Limited’s upcoming earnings report date?
SMS Pharmaceuticals Limited’s upcoming earnings report date is Jun 03, 2026 which is in 59 days.
How were SMS Pharmaceuticals Limited’s earnings last quarter?
SMS Pharmaceuticals Limited released its earnings results on Feb 07, 2026. The company reported ₹2.506 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.506.
Is SMS Pharmaceuticals Limited overvalued?
According to Wall Street analysts SMS Pharmaceuticals Limited’s price is currently Overvalued.
Does SMS Pharmaceuticals Limited pay dividends?
SMS Pharmaceuticals Limited pays a Annually dividend of ₹0.4 which represents an annual dividend yield of 0.13%. See more information on SMS Pharmaceuticals Limited dividends here
What is SMS Pharmaceuticals Limited’s EPS estimate?
SMS Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SMS Pharmaceuticals Limited have?
SMS Pharmaceuticals Limited has 93,652,030 shares outstanding.
What happened to SMS Pharmaceuticals Limited’s price movement after its last earnings report?
SMS Pharmaceuticals Limited reported an EPS of ₹2.506 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.745%.
Which hedge fund is a major shareholder of SMS Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:SMSPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, antiemetic, antiepileptic, antipsychotic, anti-hypertensive, anti-anginal, anti-viral, urinary antispasmodic, and anti-retroviral APIs. It is also involved in the contract research activities. The company also exports its products. SMS Pharmaceuticals Limited was incorporated in 1987 and is based in Hyderabad, India.
Technical Analysis
Bajaj Healthcare Ltd
―
Indoco Remedies Limited
―
Medi Assist Healthcare Services Limited
―
Morepen Laboratories Limited
―
Solara Active Pharma Sciences Ltd.
―